Regeneration of the pancreatic beta cell. Export

@article{citeulike:171477, abstract = {Type 1 diabetes is the result of an autoimmune attack against the insulin-producing beta cells of the endocrine pancreas. Current treatment for patients with type 1 diabetes typically involves a rigorous and invasive regimen of testing blood glucose levels many times a day along with subcutaneous injections of recombinant DNA-derived insulin. Islet transplantation, even with its substantially improved outcome in recent years, is still not indicated for pediatric patients. However, in light of the fact that some regenerative capabilities of the endocrine pancreas have been documented and recent research has shown that human ES cell lines can be derived in vitro, this review discusses whether it is practical or even possible to combine these lines of research to more effectively treat young diabetic patients.}, address = {Division of Immunogenetics, Department of Pediatrics, University of Pittsburgh School of Medicine, Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania 15213-3205, USA. mnt@pitt.edu}, author = {Trucco, M.}, citeulike-article-id = {171477}, citeulike-linkout-0 = {http://dx.doi.org/10.1172/JCI200523935}, citeulike-linkout-1 = {http://view.ncbi.nlm.nih.gov/pubmed/15630433}, citeulike-linkout-2 = {http://www.hubmed.org/display.cgi?uids=15630433}, doi = {10.1172/JCI200523935}, issn = {0021-9738}, journal = {J Clin Invest}, keywords = {beta-cell, diabetes, pancreas, stem-cell}, month = {January}, number = {1}, pages = {5--12}, posted-at = {2005-04-26 17:09:50}, priority = {2}, title = {Regeneration of the pancreatic beta cell.}, url = {http://dx.doi.org/10.1172/JCI200523935}, volume = {115}, year = {2005} }

TY - JOUR ID - citeulike:171477 L3 - citeulike-article-id:171477 N2 - Type 1 diabetes is the result of an autoimmune attack against the insulin-producing beta cells of the endocrine pancreas. Current treatment for patients with type 1 diabetes typically involves a rigorous and invasive regimen of testing blood glucose levels many times a day along with subcutaneous injections of recombinant DNA-derived insulin. Islet transplantation, even with its substantially improved outcome in recent years, is still not indicated for pediatric patients. However, in light of the fact that some regenerative capabilities of the endocrine pancreas have been documented and recent research has shown that human ES cell lines can be derived in vitro, this review discusses whether it is practical or even possible to combine these lines of research to more effectively treat young diabetic patients. IS - 1 JF - J Clin Invest SN - 0021-9738 AD - Division of Immunogenetics, Department of Pediatrics, University of Pittsburgh School of Medicine, Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania 15213-3205, USA. mnt@pitt.edu EP - 12 TI - Regeneration of the pancreatic beta cell. VL - 115 SP - 5 KW - beta-cell KW - diabetes KW - pancreas KW - stem-cell AU - Trucco, M PY - 2005/01// UR - http://dx.doi.org/10.1172/JCI200523935 ER -